South Korea · Delayed Price · Currency is KRW Samsung Biologics Statistics
Total Valuation
KRX:207940 has a market cap or net worth of KRW 66.91 trillion. The enterprise value is 65.94 trillion.
| Market Cap | 66.91T |
| Enterprise Value | 65.94T |
Important Dates
The next estimated earnings date is Wednesday, October 21, 2026.
| Earnings Date | Oct 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:207940 has 46.24 million shares outstanding. The number of shares has decreased by -5.91% in one year.
| Current Share Class | 46.24M |
| Shares Outstanding | 46.24M |
| Shares Change (YoY) | -5.91% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 13.67% |
| Float | 11.80M |
Valuation Ratios
The trailing PE ratio is 34.08 and the forward PE ratio is 32.50. KRX:207940's PEG ratio is 1.39.
| PE Ratio | 34.08 |
| Forward PE | 32.50 |
| PS Ratio | 13.06 |
| PB Ratio | 8.00 |
| P/TBV Ratio | 8.08 |
| P/FCF Ratio | 41.09 |
| P/OCF Ratio | 27.49 |
| PEG Ratio | 1.39 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.31, with an EV/FCF ratio of 40.49.
| EV / Earnings | 33.23 |
| EV / Sales | 12.88 |
| EV / EBITDA | 23.31 |
| EV / EBIT | 28.30 |
| EV / FCF | 40.49 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.15.
| Current Ratio | 1.80 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.44 |
| Debt / FCF | 0.76 |
| Interest Coverage | 71.57 |
Financial Efficiency
Return on equity (ROE) is 18.53% and return on invested capital (ROIC) is 23.55%.
| Return on Equity (ROE) | 18.53% |
| Return on Assets (ROA) | 9.57% |
| Return on Invested Capital (ROIC) | 23.55% |
| Return on Capital Employed (ROCE) | 24.04% |
| Weighted Average Cost of Capital (WACC) | 5.33% |
| Revenue Per Employee | 961.55M |
| Profits Per Employee | 372.57M |
| Employee Count | 5,326 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.87 |
Taxes
In the past 12 months, KRX:207940 has paid 613.06 billion in taxes.
| Income Tax | 613.06B |
| Effective Tax Rate | 24.90% |
Stock Price Statistics
The stock price has decreased by -7.00% in the last 52 weeks. The beta is 0.21, so KRX:207940's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -7.00% |
| 50-Day Moving Average | 1,472.00 |
| 200-Day Moving Average | 1,578.00 |
| Relative Strength Index (RSI) | 41.51 |
| Average Volume (20 Days) | 49,073 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:207940 had revenue of KRW 5.12 trillion and earned 1.98 trillion in profits. Earnings per share was 45,556.40.
| Revenue | 5.12T |
| Gross Profit | 2.78T |
| Operating Income | 2.33T |
| Pretax Income | 2.46T |
| Net Income | 1.98T |
| EBITDA | 2.83T |
| EBIT | 2.33T |
| Earnings Per Share (EPS) | 45,556.40 |
Balance Sheet
The company has 2.21 trillion in cash and 1.24 trillion in debt, with a net cash position of 971.66 billion or 21,013.71 per share.
| Cash & Cash Equivalents | 2.21T |
| Total Debt | 1.24T |
| Net Cash | 971.66B |
| Net Cash Per Share | 21,013.71 |
| Equity (Book Value) | 8.36T |
| Book Value Per Share | 180,839.32 |
| Working Capital | 2.36T |
Cash Flow
In the last 12 months, operating cash flow was 2.43 trillion and capital expenditures -805.58 billion, giving a free cash flow of 1.63 trillion.
| Operating Cash Flow | 2.43T |
| Capital Expenditures | -805.58B |
| Depreciation & Amortization | 498.68B |
| Net Borrowing | -202.21B |
| Free Cash Flow | 1.63T |
| FCF Per Share | 35,215.66 |
Margins
Gross margin is 54.21%, with operating and profit margins of 45.48% and 38.75%.
| Gross Margin | 54.21% |
| Operating Margin | 45.48% |
| Pretax Margin | 48.08% |
| Profit Margin | 38.75% |
| EBITDA Margin | 55.21% |
| EBIT Margin | 45.48% |
| FCF Margin | 31.80% |
Dividends & Yields
KRX:207940 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.91% |
| Shareholder Yield | 5.91% |
| Earnings Yield | 2.97% |
| FCF Yield | 2.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for KRX:207940 is 1,967,520.00, which is 35.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1,967,520.00 |
| Price Target Difference | 35.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (3Y) | 16.07% |
| EPS Growth Forecast (3Y) | 27.15% |
Stock Splits
The last stock split was on October 30, 2025. It was a reverse split with a ratio of 0.6503913.
| Last Split Date | Oct 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.6503913 |
Scores
KRX:207940 has an Altman Z-Score of 12.47 and a Piotroski F-Score of 8.
| Altman Z-Score | 12.47 |
| Piotroski F-Score | 8 |